Nvidia and TSMC to unveil first domestic wafer for Blackwell chips, Axios reports
SOUTH SAN FRANCISCO - Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical-stage biopharmaceutical company with a market capitalization of $53 million, has appointed Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs, the company announced Wednesday. According to InvestingPro data, the company’s stock has shown significant momentum with a 15% return over the past week.
Polo, who holds PharmD, PhD, and MBA degrees, joins Aligos from Shionogi Inc., where he served in the same capacity. His previous experience includes leadership roles at Johnson & Johnson, where he was part of the core team for the COVID-19 vaccine and led development strategies for infectious diseases including influenza, RSV, and hepatitis C.
"As we progress ALG-000184 through the Phase 2 B-SUPREME study, Ramón’s extensive regulatory expertise will be a critical component as we think about the future of the program," said Sushmita Chanda, Executive Vice President and Chief Development Officer at Aligos, in a press release statement. While the company’s current ratio of 6.31 indicates strong short-term financial stability, InvestingPro analysis reveals the company is quickly burning through cash, a common characteristic of clinical-stage biotech companies.
Polo’s appointment comes at a strategic time for Aligos, which focuses on developing therapies for liver and viral diseases. The company is currently advancing its ALG-000184 program through Phase 2 clinical trials. Based on InvestingPro’s Fair Value analysis, the stock appears to be trading below its intrinsic value. Subscribers to InvestingPro can access 10 additional investment tips and comprehensive financial metrics for Aligos.
"I look forward to developing and implementing a comprehensive plan to aid in the continued development of ALG-000184," Polo stated.
Polo received his PharmD, Master of Science, and PhD from the Complutense University of Madrid, and obtained his Global MBA from the IESE Business School, University of Navarra. He also attended Harvard Business School’s Program for Management Development.
Aligos Therapeutics is focused on treatments for chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis, and coronaviruses.
In other recent news, Aligos Therapeutics has initiated dosing in the Phase 2 B-SUPREME study for its investigational drug ALG-000184, aimed at treating chronic hepatitis B virus (HBV) infection. This trial will involve approximately 200 untreated adult subjects and will span 48 weeks to assess the drug’s safety, efficacy, pharmacokinetics, and various biomarkers of HBV infection. The study is a randomized, double-blind comparison of ALG-000184 monotherapy against tenofovir disoproxil fumarate. Additionally, H.C. Wainwright has initiated coverage of Aligos Therapeutics with a Buy rating, setting a price target of $50.00. The firm bases its optimism on the potential of ALG-000184 to become a new standard-of-care for chronic HBV suppression. This investigational compound is also anticipated to serve as an oral backbone for future functional cure regimens. These developments highlight the company’s ongoing efforts in advancing HBV treatment options.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.